Chemistry:AGN-1135
From HandWiki
AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1][2] It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022).[1][2] Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor.[1] Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer.[1] In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.[1]
See also
- Deprenyl (the racemic form of selegiline)
- SU-11739 (the racemic N-methyl analogue of rasagiline)
- Desmethylselegiline (DMS; the N-demethylated analogue of selegiline)
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "The discovery and development of rasagiline as a new anti-Parkinson medication". Journal of Neural Transmission 127 (2): 125–130. February 2020. doi:10.1007/s00702-020-02142-w. PMID 31974721.
- ↑ 2.0 2.1 "Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease". Journal of Clinical Pharmacology 45 (8): 878–894. August 2005. doi:10.1177/0091270005277935. PMID 16027398. http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=16027398.
 |  |
